• Record revenue, with new customers significantly increasing order numbers
• Existing infant formula customers expanded into adult, senior, and children's nutrition segments
• Appointment of distributors across North America, Asia and Europe improving access to markets

Clover Corporation Ltd, a global leader in microencapsulated omega-3 oils for infant formula and functional foods, has reported strong financial results for the fiscal year ended 31 July 2025 (FY25). The company achieved record revenue of $86 million, up 38% from the prior year, and NPAT growth of 382% to $7 million. The results were driven by several key factors, including new customers significantly increasing order numbers, existing infant formula customers expanding into adult, senior, and children's nutrition segments, and the appointment of distributors across North America, Asia, and Europe to improve market access. Clover also applied for a global patent for its CholineXcel technology, which overcomes challenges in handling and stability for its customers.Operationally, the company's crude oil production facility in Ecuador commenced deliveries in November 2024, now supplying around 30% of Clover's tuna oil requirements. The Melody Dairies facility in New Zealand also saw improved performance, with increased production volumes lowering per-unit costs and supporting stronger margins.Clover's balance sheet was strengthened during the year, with net assets increasing to $72.2 million. The company repaid its non-current borrowings, significantly improving gearing and providing greater financial flexibility. The strong cash position of $8.7 million, along with disciplined capital management, allowed for continued investment in product development and infrastructure.Looking ahead, Clover is focused on accelerating the commercialization of new products, expanding its market reach, diversifying into adjacent high-growth markets, and deepening customer value and retention. The Board expects the first half of FY26 to be in line with the prior corresponding period.

Based on the current market and global conditions, the Board expects 1H FY26 to be in line with 1H FY25.

Clover is focused on accelerating the commercialization of new products, expanding its market reach, diversifying into adjacent high-growth markets, and deepening customer value and retention.